Synaptic Imaging and Cognitive Decline in Alzheimer's Disease

Alzheimer’s disease is characterised by progressive loss of synaptic connectivity that underlies the deterioration of memory and other cognitive functions. Synaptic imaging has emerged as a vital tool for visualising this synaptopathy in living patients, offering insights into regional vulnerability and temporal progression. Leading approaches include positron emission tomography (PET) with radiotracers directed at synaptic vesicle glycoprotein 2A (SV2A) to quantify synaptic density, alongside complementary methods such as tau PET to map neurofibrillary pathology and advanced magnetic resonance techniques to assess structural and functional alterations. High-resolution optical microscopy in experimental models further elucidates the molecular mechanisms by which amyloid-β oligomers, tau aggregates and genetic risk factors disrupt synaptic architecture and plasticity. By correlating in vivo measures of synaptic loss with cognitive performance, these technologies are refining early diagnosis, stratifying disease stages and evaluating the efficacy of emerging synapse-targeted therapies. Future directions include longitudinal multimodal studies to track synaptic dynamics, integration with fluid biomarkers and personalised imaging protocols to guide precision interventions.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Synaptic Imaging and Cognitive Decline in Alzheimer's Disease publication trend

The graph below shows the total number of articles in synaptic imaging and cognitive decline in alzheimer's disease across all publications each year (not limited to Nature Index journals).

Technical terms

SV2A: A presynaptic membrane protein targeted by PET radiotracers to measure synaptic density in vivo.

Positron Emission Tomography (PET): A molecular imaging technique that uses radiotracers to visualise and quantify specific biological targets.

Synaptic density: The concentration of synaptic contacts per unit brain volume, indicative of neural connectivity and plasticity.

Tau pathology: Abnormal accumulation of tau protein in neurofibrillary tangles, contributing to synaptic dysfunction and neuronal loss.

APOE ε4 allele: A genetic variant that increases risk for Alzheimer’s disease and amplifies susceptibility of synapses to pathological insults.

References

1. In vivo imaging of synaptic density in neurodegenerative disorders with positron emission tomography: A systematic review. Ageing Research Reviews (2024).
2. APOE ε4 is associated with decreased synaptic density in cognitively impaired participants. Alzheimer's & Dementia (2024).
3. In vivo tau pathology is associated with synaptic loss and altered synaptic function. Alzheimer's Research & Therapy (2021).